Grapefruit Juice and its Constituents Augment Colchicine Intestinal Absorption: Potential Hazardous Interaction and the Role of P-Glycoprotein
- 459 Downloads
To investigate the potential interaction between grapefruit juice (GFJ) and the oral microtubule polymerization inhibitor colchicine, a P-gp and CYP3A4 substrate.
Colchicine intestinal epithelial transport was investigated across Caco-2 cell monolayers in both AP–BL and BL–AP directions, in the absence/presence of known P-gp inhibitors (verapamil and quinidine). The concentration-dependent effects of GFJ and its major constituents (6′-7′-dihydroxybergamottin, naringin and naringenin) on colchicine Caco-2 mucosal secretion were examined. The effect of GFJ on colchicine intestinal-permeability was then investigated in-situ in the rat perfusion model, in both jejunum and ileum.
Colchicine exhibited 20-fold higher BL–AP than AP–BL Caco-2 permeability, indicative of net mucosal secretion, which was reduced by verapamil/quinidine. Colchicine AP–BL permeability was increased and BL–AP was decreased by GFJ in a concentration-dependent manner (IC50 values of 0.75% and 0.46% respectively), suggesting inhibition of efflux transport, rather than metabolizing enzyme. Similar effects obtained following pre-experiment incubation with GFJ, even though the juice was not present throughout the transepithelial study. 6′-7′-Dihydroxybergamottin, naringin and naringenin displayed concentration-dependent inhibition on colchicine BL–AP secretion (IC50 values of 90, 592 and 11.6 μM respectively). Ten percent GFJ doubled colchicine rat in-situ ileal permeability, and increased 1.5-fold jejunal permeability.
The data suggest that GFJ may augment colchicine oral bioavailability. Due to colchicine narrow therapeutic-index and severely toxic side-effects, awareness of this interaction is prudent.
KEY WORDScolchicine drug interaction grapefruit juice intestinal permeability P-glycoprotein
- 20.T. Tateishi, P. Soucek, Y. Caraco, F. P. Guengerich, and A. J. J. Wood. Colchicine biotransformation by human liver microsomes: identification of cyp3A4 as the major isoform responsible for colchicine demethylation. Biochem. Pharmacol. 53:111 (1997) doi: 10.1016/S0006-2952(96)00693-4.PubMedCrossRefGoogle Scholar
- 21.B. Bittner, A. Guenzi, P. Fullhardt, G. Zuercher, R. Gonzalez, and R. Mountfield. Improvement of the bioavailability of colchicine in rats by co-administration of D-alpha-tocopherol polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid. Arzneimittelforschung. 52:684–688 (2002).PubMedGoogle Scholar
- 24.M. Rochdi, A. Sabouraud, C. Girre, R. Venet, and J. Scherrmann. Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. Eur. J. Clin. Pharmacol. 46:351–354 (1994) doi: 10.1007/BF00194404.PubMedCrossRefGoogle Scholar
- 29.P. Anderle, E. Niederer, W. Rubas, C. Hilgendorf, H. Spahn-Langguth, H. Wunderli-Allenspach, H. P. Merkle, and P. Langguth. P-glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels. J. Pharm. Sci. 87:757–762 (1998) doi: 10.1021/js970372e.PubMedCrossRefGoogle Scholar
- 32.E. Lipka, H. Lennernas, and G. L. Amidon. Interspecies correlation of permeability estimates: the feasibility of animal data for predicting oral absorption in humans. Pharm. Res. 12:S–311 (1995).Google Scholar
- 33.A. Dahan, B. T. West, and G. L. Amidon. Segmental-dependent membrane permeability along the intestine following oral drug administration: evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. Eur. J. Pharm. Sci. in press (2008) doi: 10.1021/mp800088f.
- 38.I. F. N. Hung, A. K. L. Wu, V. C. C. Cheng, B. S. F. Tang, K. W. To, C. K. Yeung, P. C. Y. Woo, S. K. P. Lau, B. M. Y. Cheung, and K. Y. Yuen. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin. Infect. Dis. 41:291–300 (2005) doi: 10.1086/431592.PubMedCrossRefGoogle Scholar
- 40.X. Cao, L. X. Yu, C. Barbaciru, C. P. Landowski, H. C. Shin, S. Gibbs, H. A. Miller, G. L. Amidon, and D. Sun. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. Mol. Pharmaceutics. 2:329–340 (2005) doi: 10.1021/mp0499104.CrossRefGoogle Scholar
- 41.I. Gonzalez-Alvarez, C. Fernandez-Teruel, V. G. Casabo-Alos, T. M. Garrigues, J. E. Polli, A. Ruiz-Garcia, and M. Bermejo. In situ kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation with in vitro results. Biopharm. Drug Dispos. 28:229–239 (2007) doi: 10.1002/bdd.548.PubMedCrossRefGoogle Scholar
- 42.B. Valenzuela, A. Nacher, P. Ruiz-Carretero, A. Martin-Villodre, G. Lopez-Carballo, and D. Barettino. Profile of P-glycoprotein distribution in the rat and its possible influence on the salbutamol intestinal absorption process. J. Pharm. Sci. 93:1641–1648 (2004) doi: 10.1002/jps.20071.PubMedCrossRefGoogle Scholar
- 44.N. A. Kasim, M. Whitehouse, C. Ramachandran, M. Bermejo, H. Lennernas, A. S. Hussain, H. E. Junginger, S. A. Stavchansky, K. K. Midha, V. P. Shah, and G. L. Amidon. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharmaceutics. 1:85–96 (2004) doi: 10.1021/mp034006h.CrossRefGoogle Scholar
- 45.A. Dahan and G. L. Amidon. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol. Pharmaceutics in press (2008) doi: 10.1016/j.ejps.2008.10.013.
- 50.H. Takanaga, A. Ohnishi, H. Murakami, H. Matsuo, S. Higuchi, A. Urae, S. Irie, H. Furuie, K. Matsukuma, M. Kimura, K. Kawano, Y. Orii, T. Tanaka, and Y. Sawada. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin. Pharmacol. Ther. 67:201 (2000) doi: 10.1067/mcp.2000.104215.PubMedCrossRefGoogle Scholar
- 52.W. V. De Castro, S. Mertens-Talcott, H. Derendorf, and V. Butterweck. Grapefruit juice–drug interactions: grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J. Pharm. Sci. 96:2808–2817 (2007) doi: 10.1002/jps.20975.PubMedCrossRefGoogle Scholar
- 53.W. V. De Castro, S. Mertens-Talcott, A. Rubner, V. Butterweck, and H. Derendorf. Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice–drug interaction studies. J. Agric. Food Chem. 54:249–255 (2006) doi: 10.1021/jf0516944.PubMedCrossRefGoogle Scholar